person · Reporting owner
MAZELSKY JONATHAN JAY
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Director | September 30, 2026 | October 03, 2026 |
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director · President and CEO | February 26, 2026 | March 02, 2026 |
| INSULET CORPPODD · Entity 3516 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DENTSPLY SIRONA Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock (Directors' Deferred Compensation) DDCSEC Table II · derivative / convertible security | Direct | 23,345.1175 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 3,323.4332 · Balance 23,345.1175 F1: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. F2: Comprised of phantom stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director.
F2: Comprised of phantom stock.
IDEXX LABORATORIES INC /DE
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,803.302 |
Ending reported balance
After 2026-02-27 transaction · row 15
15 source rows · reconciled sequenceRow 1 · 2026-02-26 · Exercise / conversion · Acquired 23,326 · Balance 106,932.302 Row 2 · 2026-02-26 · Sale · Disposed 1,281 · Balance 105,651.302 F1: Represents the weighted average price of the shares sold ranging from a low of $650.00 to a high of $650.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 3 · 2026-02-26 · Sale · Disposed 1,095 · Balance 104,556.302 F2: Represents the weighted average price of the shares sold ranging from a low of $651.06 to a high of $651.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 4 · 2026-02-26 · Sale · Disposed 1,669 · Balance 102,887.302 F3: Represents the weighted average price of the shares sold ranging from a low of $652.105 to a high of $653.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 5 · 2026-02-26 · Sale · Disposed 1,171 · Balance 101,716.302 F4: Represents the weighted average price of the shares sold ranging from a low of $653.19 to a high of $654.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 6 · 2026-02-26 · Sale · Disposed 1,111 · Balance 100,605.302 F5: Represents the weighted average price of the shares sold ranging from a low of $654.24 to a high of $655.2175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 7 · 2026-02-26 · Sale · Disposed 1,488 · Balance 99,117.302 F6: Represents the weighted average price of the shares sold ranging from a low of $655.275 to a high of $656.205 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 8 · 2026-02-26 · Sale · Disposed 1,343 · Balance 97,774.302 F7: Represents the weighted average price of the shares sold ranging from a low of $656.28 to a high of $657.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 9 · 2026-02-26 · Sale · Disposed 2,860 · Balance 94,914.302 F8: Represents the weighted average price of the shares sold ranging from a low of $657.305 to a high of $658.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 10 · 2026-02-26 · Sale · Disposed 3,660 · Balance 91,254.302 F9: Represents the weighted average price of the shares sold ranging from a low of $658.30 to a high of $659.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 11 · 2026-02-26 · Sale · Disposed 2,859 · Balance 88,395.302 F10: Represents the weighted average price of the shares sold ranging from a low of $659.31 to a high of $660.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 12 · 2026-02-26 · Sale · Disposed 1,200 · Balance 87,195.302 F11: Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 13 · 2026-02-26 · Sale · Disposed 1,000 · Balance 86,195.302 F12: Represents the weighted average price of the shares sold ranging from a low of $661.65 to a high of $662.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 14 · 2026-02-26 · Sale · Disposed 2,589 · Balance 83,606.302 F13: Represents the weighted average price of the shares sold ranging from a low of $662.72 to a high of $663.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 15 · 2026-02-27 · Exercise / conversion · Acquired 197 · Balance 83,803.302 |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $141.60 · Expires 2027-02-13 | Direct | 0 |
Reported balance
After 2026-02-26 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-02-26 · Exercise / conversion · Disposed 23,326 · Balance 0 F14: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2018. |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $505.53 · Expires 2032-02-13 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-02-27 · Exercise / conversion · Disposed 197 · Balance 0 F15: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average price of the shares sold ranging from a low of $650.00 to a high of $650.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2: Represents the weighted average price of the shares sold ranging from a low of $651.06 to a high of $651.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3: Represents the weighted average price of the shares sold ranging from a low of $652.105 to a high of $653.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F4: Represents the weighted average price of the shares sold ranging from a low of $653.19 to a high of $654.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F5: Represents the weighted average price of the shares sold ranging from a low of $654.24 to a high of $655.2175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F6: Represents the weighted average price of the shares sold ranging from a low of $655.275 to a high of $656.205 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F7: Represents the weighted average price of the shares sold ranging from a low of $656.28 to a high of $657.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F8: Represents the weighted average price of the shares sold ranging from a low of $657.305 to a high of $658.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F9: Represents the weighted average price of the shares sold ranging from a low of $658.30 to a high of $659.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F10: Represents the weighted average price of the shares sold ranging from a low of $659.31 to a high of $660.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F11: Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F12: Represents the weighted average price of the shares sold ranging from a low of $661.65 to a high of $662.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F13: Represents the weighted average price of the shares sold ranging from a low of $662.72 to a high of $663.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F14: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2018.
F15: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026.
INSULET CORP
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,496 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 141 · Balance 1,496 F1: These are deferred common stock units ("Deferred Units") received in lieu of cash compensation pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. The deferred common stock units will be converted into shares of Company common stock on a one-for-one basis upon distribution, with the value of any fractional shares paid in cash. Distribution of shares of common stock occurs, at the election of the director, either in a lump sum or in substantially equal annual installments pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These are deferred common stock units ("Deferred Units") received in lieu of cash compensation pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. The deferred common stock units will be converted into shares of Company common stock on a one-for-one basis upon distribution, with the value of any fractional shares paid in cash. Distribution of shares of common stock occurs, at the election of the director, either in a lump sum or in substantially equal annual installments pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2025 Filed Aug 9, 2025 00:38 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,095 | $626.90 | $686,458.13 |
DisclosureSEC source: 0000874716-25-000126 · wk-form4_1754699884.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,476.3016 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $626.585 to a high of $627.44 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 00:38 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 29,260 | $67.85 | $1,985,291.00 |
DisclosureSEC source: 0000874716-25-000126 · wk-form4_1754699884.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,571.3016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 28.7090 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 20:47 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 75.0272 | $16.20 | $1,215.44 |
DisclosureSEC source: 0000818479-25-000129 · form4.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,234.0374 Underlying: Common Stock · 75.0272 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F3 · shares: Comprised of phantom stock acquired as a result of accrued dividends. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 20:47 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 279.347 | $0.00 | $0.00 |
DisclosureSEC source: 0000818479-25-000129 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,091.8 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:25 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 1,561.2862 | $16.01 | $24,996.19 |
DisclosureSEC source: 0000818479-25-000108 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,159.0102 Underlying: Common Stock · 1,561.2862 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:23 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 13,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015713 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,812.453 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 20:22 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 74.8693 | $12.47 | $933.62 |
DisclosureSEC source: 0001127602-25-012078 · form4.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,597.724 Underlying: Common Stock · 74.8693 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F3 · shares: Comprised of phantom stock acquired as a result of accrued dividends. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 20:22 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 147.727 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-012078 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,932.453 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:07 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 1,687.2548 | $14.82 | $25,005.12 |
DisclosureSEC source: 0001127602-25-011123 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,522.8547 Underlying: Common Stock · 1,687.2548 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 1,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000027 · wk-form4_1739933011.xml · derivative · entry 9 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,198 Underlying: Common Stock · 1,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 958 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000027 · wk-form4_1739933011.xml · derivative · entry 8 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 958 Underlying: Common Stock · 958 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 689 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000027 · wk-form4_1739933011.xml · derivative · entry 7 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 689 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2022. F4 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2022. F4 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 1,222 | $444.53 | $543,215.66 |
DisclosureSEC source: 0000874716-25-000027 · wk-form4_1739933011.xml · nonDerivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,282.5926 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000027 · wk-form4_1739933011.xml · nonDerivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,504.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 958 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000027 · wk-form4_1739933011.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,404.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 689 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000027 · wk-form4_1739933011.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,446.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024 Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 217 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000027 · wk-form4_1739933011.xml · derivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217 Underlying: Common Stock · 217 shares Expires 2035-02-12 F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 25,932 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000027 · wk-form4_1739933011.xml · derivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,932 Underlying: Common Stock · 25,932 shares Expires 2035-02-12 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:36 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 38.5332 | $18.51 | $713.25 |
DisclosureSEC source: 0001127602-25-001224 · form4.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,835.5999 Underlying: Common Stock · 38.5332 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F3 · shares: Comprised of phantom stock acquired as a result of accrued dividends. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:36 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 115.474 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-001224 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,784.726 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| December 30, 2024 Filed Jan 2, 2025 21:05 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 1,340.4826 | $18.65 | $25,000.00 |
DisclosureSEC source: 0001127602-25-000076 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,797.0667 Underlying: Common Stock · 1,340.4826 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 20:55 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 22.846 | $24.50 | $559.73 |
DisclosureSEC source: 0001127602-24-025512 · form4.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,456.5841 Underlying: Common Stock · 22.846 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F3 · shares: Comprised of phantom stock acquired as a result of accrued dividends. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 20:55 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 80.378 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-025512 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,669.252 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 20:23 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 935.7631 | $25.13 | $23,515.73 |
DisclosureSEC source: 0001127602-24-024695 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,433.7381 Underlying: Common Stock · 935.7631 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 384 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-24-000122 · wk-form4_1723064403.xml · derivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 384 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning August 5, 2020. F3 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning August 5, 2020. F2 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning August 5, 2020. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 170 | $455.08 | $77,363.60 |
DisclosureSEC source: 0000874716-24-000122 · wk-form4_1723064403.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,732.5926 Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 384 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000122 · wk-form4_1723064403.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,902.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 22 shares purchased under the Issuer's Employee Stock Purchase Plan on March 29, 2024 and June 28, 2024. Read SEC document |
| July 12, 2024 Filed Jul 15, 2024 21:06 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 21.5597 | $25.80 | $556.24 |
DisclosureSEC source: 0001127602-24-020398 · form4.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,497.975 Underlying: Common Stock · 21.5597 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F3 · shares: Comprised of phantom stock acquired as a result of accrued dividends. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| July 12, 2024 Filed Jul 15, 2024 21:06 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 86.725 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-020398 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,588.874 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 20:16 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 994.7557 | $25.13 | $24,998.21 |
DisclosureSEC source: 0001127602-24-019548 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,476.4153 Underlying: Common Stock · 994.7557 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:28 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 7,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016577 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,502.149 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| April 12, 2024 Filed Apr 15, 2024 23:33 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 12.56 | $31.45 | $395.01 |
DisclosureSEC source: 0001127602-24-012906 · form4.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,481.6596 Underlying: Common Stock · 12.56 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F3 · shares: Comprised of phantom stock acquired as a result of accrued dividends. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| April 12, 2024 Filed Apr 15, 2024 23:33 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 26.426 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012906 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,508.149 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| March 28, 2024 Filed Mar 29, 2024 18:17 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 761.4756 | $32.83 | $24,999.24 |
DisclosureSEC source: 0001127602-24-011439 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,469.0996 Underlying: Common Stock · 761.4756 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 22:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 550 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000061 · wk-form4_1709590727.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,496.5926 Read SEC document |
| February 21, 2024 Filed Feb 22, 2024 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 483 | Not disclosed Strike: $206.94 | Not disclosed |
DisclosureSEC source: 0000874716-24-000058 · wk-form4_1708639260.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 483 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested on February 14, 2024. Read SEC document |
| February 21, 2024 Filed Feb 22, 2024 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 483 | $206.94 | $99,952.02 |
DisclosureSEC source: 0000874716-24-000058 · wk-form4_1708639260.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,046.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 1,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000039 · wk-form4_1708124192.xml · derivative · entry 13 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,298 Underlying: Common Stock · 1,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 958 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000039 · wk-form4_1708124192.xml · derivative · entry 12 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,916 Underlying: Common Stock · 958 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 689 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000039 · wk-form4_1708124192.xml · derivative · entry 11 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 689 Underlying: Common Stock · 689 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 974 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000039 · wk-form4_1708124192.xml · derivative · entry 10 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 974 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2021. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2021. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000039 · wk-form4_1708124192.xml · derivative · entry 9 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2020. F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2020. F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 178 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000039 · wk-form4_1708124192.xml · derivative · entry 8 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178 Underlying: Common Stock · 178 shares Expires 2034-02-13 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2028. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 21,335 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000039 · wk-form4_1708124192.xml · derivative · entry 7 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,335 Underlying: Common Stock · 21,335 shares Expires 2034-02-13 F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2025. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 1,839 | $560.56 | $1,030,869.84 |
DisclosureSEC source: 0000874716-24-000039 · wk-form4_1708124192.xml · nonDerivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,563.5926 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000039 · wk-form4_1708124192.xml · nonDerivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,402.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 958 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000039 · wk-form4_1708124192.xml · nonDerivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,302.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 689 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000039 · wk-form4_1708124192.xml · nonDerivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,344.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 974 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000039 · wk-form4_1708124192.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,655.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000039 · wk-form4_1708124192.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,681.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.